Neogen (NEOG) Competitors

Neogen (NASDAQ:NEOG) and Haemonetics (NYSE:HAE) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Which has more volatility & risk, NEOG or HAE?

Neogen has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500.

Do analysts rate NEOG or HAE?

Neogen currently has a consensus price target of $7.50, suggesting a potential upside of 52.19%. Haemonetics has a consensus price target of $97.30, suggesting a potential upside of 30.52%. Given Neogen's higher probable upside, equities research analysts plainly believe Neogen is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neogen	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Haemonetics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Is NEOG or HAE more profitable?

Haemonetics has a net margin of 12.32% compared to Neogen's net margin of -53.56%. Haemonetics' return on equity of 26.37% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neogen	-53.56%	2.69%	1.82%
Haemonetics	12.32%	26.37%	9.22%

Do insiders & institutionals have more ownership in NEOG or HAE?

96.7% of Neogen shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 1.1% of Neogen shares are held by insiders. Comparatively, 1.8% of Haemonetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has better earnings & valuation, NEOG or HAE?

Haemonetics has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neogen	$924.22M	1.16	-$9.42M	-$2.23	-2.21
Haemonetics	$1.36B	2.63	$167.68M	$3.31	22.52

Does the media prefer NEOG or HAE?

In the previous week, Haemonetics had 3 more articles in the media than Neogen. MarketBeat recorded 19 mentions for Haemonetics and 16 mentions for Neogen. Haemonetics' average media sentiment score of 0.58 beat Neogen's score of 0.29 indicating that Haemonetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neogen	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Haemonetics	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Haemonetics beats Neogen on 15 of the 17 factors compared between the two stocks.